-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMCM-113V in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMCM-113V in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details:IMCM-113V is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – interferon beta-1a in Chronic Obstructive Pulmonary Disease (COPD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. interferon beta-1a in Chronic Obstructive Pulmonary Disease (COPD) Drug Details: Interferon beta-1a (AZD9412, SNG001)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AD-214 in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Idiopathic Pulmonary Fibrosis Drug Details: AD-214 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Acrixolimab in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Acrixolimab in Solid Tumor Drug Details: Acrixolimab (YBL-006) is under development for the treatment...
-
Company Profile
![]()
Synairgen Plc – Company Profile
Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma, COVID-19 and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) in Phase II clinical trials for chronic obstructive pulmonary disease (COPD) and COVID-19. The company in partnership with Pharmaxis investigating, lysyl oxidase-like protein 2 (LOXL2), a small molecule inhibitor in Phase I clinical trials for the treatment of...
Add to Basket -
Sector Analysis
![]()
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – August 2022
The urgent need for effective preventive vaccine and efficacious therapeutics for COVID-19 has given rise to an unprecedented pace of R&D by the biopharmaceutical industry, coupled with substantial investment by governments, non-profit agencies, and other stakeholders. There are currently more than 1,800Â assets in development for COVID-19, the majority of which are very early-stage or have little data available. The Coronavirus Disease 2019 (COVID-19) clinical and commercial analyzer report looks at the data from clinical trials for vaccines and therapeutics either...
-
Sector Analysis
![]()
COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships
This report examines contract manufacturing agreements for vaccines and therapies targeting COVID-19. It reports that there are more than 1,000 vaccines and therapies in development for COVID-19, and 36 vaccines and therapies approved (or granted emergency use authorization) for COVID-19 (as of report publication). At the beginning of the pandemic, slightly more than half of these agreements were for vaccines; this proportion has risen and continues to rise, as several vaccines have proven their safety and efficacy, received approval, and...
-
Product Insights
![]()
Chronic Obstructive Pulmonary Disease (COPD) Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Obstructive Pulmonary Disease (COPD) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Obstructive Pulmonary Disease (COPD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
![]()
Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
![]()
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.